Ditchcarbon
  • Contact
  1. Organizations
  2. VIVUS, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 9 months ago

VIVUS, Inc. Sustainability Profile

Company website

VIVUS, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States and focuses on developing innovative therapies for obesity and sexual health. Founded in 1991, the company has achieved significant milestones, including the launch of its flagship product, Qsymia, which addresses obesity management through a unique combination of active ingredients. With a commitment to advancing patient care, VIVUS also offers the erectile dysfunction treatment, Stendra, which stands out for its rapid onset of action. The company has established a strong market position, recognised for its dedication to research and development in niche therapeutic areas. VIVUS continues to strive for excellence, aiming to improve the quality of life for patients through its specialised products and services.

DitchCarbon Score

How does VIVUS, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

25

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

34

Industry Benchmark

VIVUS, Inc.'s score of 25 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.

44%

Let us know if this data was useful to you

VIVUS, Inc.'s reported carbon emissions

VIVUS, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Icahn Enterprises L.P., which may influence its climate strategy and reporting practices. While VIVUS, Inc. has not established specific reduction targets or commitments under the Science Based Targets initiative (SBTi), it is important to note that its climate commitments may be informed by the broader sustainability initiatives of its parent company. Icahn Enterprises L.P. has been involved in various environmental initiatives, which could potentially impact VIVUS's approach to carbon emissions and climate action. As of now, VIVUS, Inc. has not publicly disclosed any significant climate pledges or reduction initiatives. The company’s future climate commitments and emissions data may evolve as it aligns with industry standards and practices.

How Carbon Intensive is VIVUS, Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. VIVUS, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is VIVUS, Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for VIVUS, Inc. is in US, which has a low grid carbon intensity relative to other regions.

VIVUS, Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

VIVUS, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare VIVUS, Inc.'s Emissions with Industry Peers

Genentech

US
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated 17 days ago

Boehringer Ingelheim

DE
•
Medical, precision and optical instruments, watches and clocks (33)
Updated 14 days ago

Astra Zeneca

GB
•
Pharmaceutical Preparation Manufacturing
Updated 16 days ago

Novartis

CH
•
Pharmaceutical Preparation Manufacturing
Updated 23 minutes ago

Glaxosmithkline

GB
•
Pharmaceutical Preparation Manufacturing
Updated 6 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251119.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
Available onAWS Marketplace logo
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy